|
AstraZeneca PLC on Thursday said that new analyses from a phase 3 treatment trial show the potential of its Covid drug Evusheld to reduce severity and mortality.
New Tackle phase 3 data will highlight the activity of Evusheld against circulating Covid variants. Further, the Cambridge-based pharmaceutical company will present new data on its Covid vaccine Vaxzevria and its respiratory syncytial virus treatment Beyfortus.
In September, Beyfortus received recommendation for EU approval from the EU's European Medicine's Authority's Committee for Medicinal Products for Human Use. The drug was developed in cooperation with French partner Sanofi SA.
RSV is a common contagious virus affecting the lungs and breathing passages with no vaccines currently available for treatment. London-based pharmaceutical firm GSK PLC in June said it is close to developing the world's first RSV vaccine.
AstraZeneca will present the new data at the annual IDWeek conference in Washington DC that runs since Wednesday and until Sunday.
AstraZeneca shares were down 1.7% to 9,638.25 pence each in London on Thursday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
